Day: March 16, 2023

Delivered Quarterly Revenue of $47.3 Million and Full Year Revenue of $216.9 Million Expanded Quarterly Gross Margin by 95 Basis Points to 38.6% and Full Year Gross Margin by 96 Basis Points to 36.4% Generated Full Year Cash Flow from Operations of $16.5 Million and Free Cash Flow of $11.2 Million; Deployed $11.3 Million to Share Repurchases During 2022 Forecasts Lower Revenues in 2023; Hired Two New Senior Leaders Focused on Growth and Customer SolutionsASHBURN, Va., March 16, 2023 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced financial results for the fourth quarter and full year 2022. “We delivered $47.3 million of revenue in the fourth quarter of 2022, and expanded gross margin...

– Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway – – Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected into 2026 – PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the full-year ended December 31, 2022. “We are excited about the significant progress of our next generation platforms for iNK and gamma delta iT product candidates, including the commencement of our Phase 1 ELiPSE-1 trial for CNTY-101. We are well-positioned for a productive 2023 as we continue building on the foundational...

Reports Second Year of Record Annual Sales with Comparable Sales Growth of 10.9%; Full-Year Sales of $545.8 million, Net Income of $89.1 million, $1.33 EPS, Adjusted EBITDA of $73.8 million CANTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported financial results for the fourth quarter and fiscal year 2022. Fourth Quarter HighlightsTotal sales for the fourth quarter were $143.9 million, up 7.8% from $133.5 million for fiscal 2021. Comparable sales for the fourth quarter increased 10.8% as compared to the fourth quarter of fiscal 2021. Net income for the fourth quarter was $8.3 million, or $0.13 per diluted share, as compared to net income of $9.9 million, or $0.14 per diluted share, for...

— NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year — Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March 16, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek generated total revenue of $160.3 million, primarily as a result of strong growth in NUZYRA® commercial revenue. NUZYRA generated full-year net U.S. sales of $136.8 million in 2022, comprised of $98.7 million from the core commercial business, a 45% increase over the prior year, and $38.1 million from the second procurement of...

Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing Disclosure of initial data from Phase 1 arm of study expected in second half of 2023 MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression Nomination of multiple development candidates anticipated in 2023 Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025BOSTON, March 16, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided corporate updates. “Last year...

Strong order book growth; initial deliveries slated to begin in 4Q23Achieved key development milestones in 2022 on time and in line with budget with total operating expenses of $127 million Liquidity of $154 million supports anticipated non-GAAP operating expense of $70-$75 million for 2023 with P7 program fully funded into commercialization Strong order book growth for Powered by REE vehicles growing customer base from 2 to 8 since reporting 3Q22 results with 35 firm orders as of today Delivered 2 prototypes to an OEM for customer evaluation and testing Grew our go to market strategy by achieving direct sales and entering into additional dealership agreements in the US Provided suppliers with 2023-24 production forecast; built the first batch of production intent P7 vehicles for validation; certification activities underway Company...

Maroussi, Greece, March 16, 2023 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (the “Company” or “Pyxis Tankers”), an international pure-play product tanker company, today announced unaudited results for the three months and year ended December 31, 2022. Summary For the three months ended December 31, 2022, our Revenues, net were $18.4 million. For the same period, our time charter equivalent (“TCE”) revenues were $13.8 million, an increase of approximately $10.0 million or 256% from the comparable quarter in 2021. Our net income attributable to common shareholders for the three months ended December 31, 2022 was $6.5 million, representing an increase of $12.1 million from a net loss of $5.6 million in the comparable period in 2021. For the fourth quarter of 2022, the net income per share was $0.61 basic and $0.53 diluted compared to a...

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate UpdateClinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023 ACI-24.060 anti-amyloid-beta vaccine for Alzheimer’s disease (AD) showed positive initial safety and immunogenicity in Phase 1b/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024 ACI-35.030 anti-pTau vaccine for AD selected for further development by partner; anticipated H2 2023 initiation of next trial in AD to be followed by milestone payment 2022 cash burn of CHF 70.9 million was better than guidance (2022: CHF 75-80 million) resulting in strong end of year financial position of CHF 122.6 million providing runway into...

MIDDLETOWN, R.I., March 16, 2023 (GLOBE NEWSWIRE) — KVH Industries, Inc., (Nasdaq: KVHI), reported financial results for the quarter and full year ended December 31, 2022 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company’s website. Fourth Quarter 2022 HighlightsTotal revenues from continuing operations increased by 2% in the fourth quarter of 2022 to $36.0 million from $35.3 million in the fourth quarter of 2021.Our VSAT Broadband airtime revenue increased 12% year-over-year to $26.8 million, despite the shutdown of our legacy network on December 31, 2021.Net income from continuing operations in the fourth quarter of 2022 was $0.6 million, or $0.03 per...